World Allergy Organization Journal (May 2025)

ARIA-Italy multidisciplinary consensus on nasal polyposis and biological treatments: Update 2025

  • Carlo Lombardi, MD,
  • Rikki F. Canevari, MD,
  • Diego Bagnasco, MD,
  • Maria Beatrice Bilò, MD,
  • Giorgio Walter Canonica, MD,
  • Cristiano Caruso, MD,
  • Paolo Castelnuovo, MD,
  • Lorenzo Cecchi, MD,
  • Orietta Calcinoni, MD,
  • Mauro Carone, MD,
  • Marco Cassatella, MD,
  • Renato Cutrera, MD,
  • Gianni Danesi, MD,
  • Eugenio De Corso, MD,
  • Mario Di Gioacchino, MD,
  • Fabiano Di Marco, MD,
  • Stefania Gallo, MD,
  • Matteo Gelardi, MD,
  • Enrico Heffler, MD,
  • Clara Imperatore, MD,
  • Cristiana Indolfi, MD,
  • Massimo Landi, MD,
  • Amelia Licari, MD,
  • Francesco Liotta, MD,
  • Alberto Macchi, MD,
  • Luca Malvezzi, MD,
  • Sara Manti, MD,
  • Francesco Menzella, MD,
  • Claudio Micheletto, MD,
  • Fabio Midulla, MD,
  • Michele Miraglia Del Giudice, MD,
  • Antonino Musarra, MD,
  • Vincenzo Patella, MD,
  • Diego Peroni, MD,
  • Laura Petrarca, MD,
  • Giorgio Piacentini, MD,
  • Alessandro Pusateri, MD,
  • Veronica Seccia, MD, PhD,
  • Gianenrico Senna, MD,
  • Adriano Vaghi, MD,
  • Carlo Vancheri, PhD,
  • Giovanni Passalacqua, MD,
  • S. Arasi,
  • D. Bagnasco,
  • I. Baiardini,
  • S. Barbaglia,
  • F. Barosso,
  • R. Bernardini,
  • A. Berti,
  • B. Bilò,
  • L. Brussino,
  • F.R. Canevari,
  • G.W. Canonica,
  • C. Caruso,
  • A.A. Caruso,
  • A.G. Caviglia,
  • L. Cecchi,
  • P. Comberiati,
  • L. Cosmi,
  • M. Cottini,
  • M. Crivellaro,
  • D. Di Bona,
  • A. Fiocchi,
  • S. Frateiacci,
  • M. Gelardi,
  • G. Guida,
  • E. Heffler,
  • C. Incorvaia,
  • M. Landi,
  • M.A. Licari,
  • L. Malvezzi,
  • M. Milanese,
  • F. Mina,
  • E. Nettis,
  • G. Pala,
  • V. Patella,
  • D. Peroni,
  • S. Peveri,
  • F. Puggioni,
  • A. Pusateri,
  • O. Rossi,
  • E. Ridolo,
  • E. Savi,
  • J. Schroeder,
  • V. Seccia,
  • G.E. Senna,
  • M. Triggiani,
  • M. Uberti,
  • G. Varricchi,
  • M.T. Ventura,
  • M.T. Zedda

DOI
https://doi.org/10.1016/j.waojou.2025.101058
Journal volume & issue
Vol. 18, no. 5
p. 101058

Abstract

Read online

In recent years, it was recognized that type-2 inflammation connects nasal polyposis and severe asthma (SA) in addition to other type-2 diseases. Thus, some biological drugs developed for SA appeared to exert a favourable effect also in nasal polyposis. So far, there are several trials supporting this concept; therefore, some monoclonal antibodies already used for SA were assessed also in chronic rhinosinusistis with nasal polyposis (CRSwNP), with promising results.Since different specialists are involved in the management of nasal polyposis (eg, pulmonologists, ENT specialists, allergists, immunologists, pediatricians), it was felt that an updated educational and informative document was needed to better identify the indications of biological therapies in nasal polyposis. We collected the main Italian scientific societies, and prepared (under the umbrella of Allergic Rhinitis and its Impact on Asthma, ARIA) a document endorsed by all societies, to provide a provisional statement for the future use of monoclonal antibodies (MAbs) as a medical treatment for polyposis, possibly associated with SA. The above mentioned document was the first endorsed document on this aspect, and the additional evidence required an update. The current pathogenic knowledge and the experimental evidence are herein reviewed, and some suggestions for a correct prescription and follow-up are provided.

Keywords